Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers
Yıl: 2022 Cilt: 6 Sayı: 1 Sayfa Aralığı: 12 - 15 Metin Dili: İngilizce DOI: 10.14744/ejmo.2022.74316 İndeks Tarihi: 18-06-2022
Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers
Öz: Immunotherapies (ICI) are used alone, in combination with chemotherapy (CT) or targeted therapy in many cancers.
All current developments will be reviewed in gastrointetsinal tract tumor treatment.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191–203.
- 2. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506–17.
- 3. Chen, Li-Tzong, Yoon-Koo Kang, Taroh Satoh, Yee Chao, Ken Kato, Hyun Cheol Chung, et al. A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. J Clin Oncol 2020;38:383.
- 4. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123–33.
- 5. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1571–80.
- 6. Moehler, M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 2020;31:1191.
- 7. Boku N, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION- 4 (ONO-4538-37) study. Ann Oncol 2020;31:1142–215.
- 8. Kato K, Sun JM, Shah MA, Enzinger PC, Adenis A, Doi T, et al. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol 2020;31:1192–3.
- 9. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers (Version 2.2021) and Gastric Cancers (Version 2.2021). Available at: https://www.nccn. org/professionals/physician_gls/pdf/esophageal.pdf. Accessed Feb 4, 2022.
- 10. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, openlabel, phase 1b trial. Lancet Oncol 2016;17:717–26.
- 11. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 2019;22:828–37.
- 12. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol 2019;5:546–50.
- 13. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al; KEYNOTE-181 Investigators. Randomized phase III KEYNOTE- 181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 2020;38:4138–48.
- 14. Martinelli E, Martini G, Troiani T, Pietrantonio F, Avallone A, Normanno N, et al. Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study. Ann Oncol 2020;31:409–10.
- 15. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–91
- 16. Overman M, Lonardi S, Wong M, Lenz HJ, Gelsomino F, Aglietta M, et al. Nivolumab (NIVO)+ low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability- high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. J Clin Oncol 2019;37:635.
- 17. Lenz HJ, Lonardi S, Zagonel V, Van Cutsem E, Limon ML, Wong KYM, et al. Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/ dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy: Two-year clinical update. J Clin Oncol 2021;39:58.
- 18. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatelliteinstability- high advanced colorectal cancer. N Engl J Med 2020;383:2207–18.
- 19. National Comprehensive Cancer Network. Colon Cancer (Version 2.2021) and Rectum Cancer (Version 1.2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/ colon.pdf. Accessed Feb 4, 2022.
| APA | karabulut s, TOPALGOKCELİ M, TASTEKIN D (2022). Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. , 12 - 15. 10.14744/ejmo.2022.74316 |
| Chicago | karabulut senem,TOPALGOKCELİ Meltem Selam,TASTEKIN DIDEM Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. (2022): 12 - 15. 10.14744/ejmo.2022.74316 |
| MLA | karabulut senem,TOPALGOKCELİ Meltem Selam,TASTEKIN DIDEM Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. , 2022, ss.12 - 15. 10.14744/ejmo.2022.74316 |
| AMA | karabulut s,TOPALGOKCELİ M,TASTEKIN D Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. . 2022; 12 - 15. 10.14744/ejmo.2022.74316 |
| Vancouver | karabulut s,TOPALGOKCELİ M,TASTEKIN D Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. . 2022; 12 - 15. 10.14744/ejmo.2022.74316 |
| IEEE | karabulut s,TOPALGOKCELİ M,TASTEKIN D "Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers." , ss.12 - 15, 2022. 10.14744/ejmo.2022.74316 |
| ISNAD | karabulut, senem vd. "Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers". (2022), 12-15. https://doi.org/10.14744/ejmo.2022.74316 |
| APA | karabulut s, TOPALGOKCELİ M, TASTEKIN D (2022). Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology, 6(1), 12 - 15. 10.14744/ejmo.2022.74316 |
| Chicago | karabulut senem,TOPALGOKCELİ Meltem Selam,TASTEKIN DIDEM Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology 6, no.1 (2022): 12 - 15. 10.14744/ejmo.2022.74316 |
| MLA | karabulut senem,TOPALGOKCELİ Meltem Selam,TASTEKIN DIDEM Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology, vol.6, no.1, 2022, ss.12 - 15. 10.14744/ejmo.2022.74316 |
| AMA | karabulut s,TOPALGOKCELİ M,TASTEKIN D Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 12 - 15. 10.14744/ejmo.2022.74316 |
| Vancouver | karabulut s,TOPALGOKCELİ M,TASTEKIN D Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 12 - 15. 10.14744/ejmo.2022.74316 |
| IEEE | karabulut s,TOPALGOKCELİ M,TASTEKIN D "Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers." Eurasian Journal of Medicine and Oncology, 6, ss.12 - 15, 2022. 10.14744/ejmo.2022.74316 |
| ISNAD | karabulut, senem vd. "Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers". Eurasian Journal of Medicine and Oncology 6/1 (2022), 12-15. https://doi.org/10.14744/ejmo.2022.74316 |
